Madewell, et al. 1994. Radiation therapy of ceruminous gland carcinomas in dogs and cats. J Am Vet Med Assoc 205:566–569.682 Theon, A.P., B.R. Madewell, M.F. Harb, et al. 1993. Megavoltage irradiation of neoplasms of the nasal and paranasal cavities in 77 dogs. J Am Vet Med Assoc 202:1469–1475.
683 Theon, A.P., B.R. Madewell, A.S. Moore, et al. 1991. Localized thermo‐cisplatin therapy: A pilot study in spontaneous canine and feline tumours. Int J Hyperthermia 7:881–892.
684 Theon, A.P., S.L. Marks, E.S. Feldman, et al. 2000. Prognostic factors and patterns of treatment failure in dogs with unresectable differentiated thyroid carcinomas treated with megavoltage irradiation. J Am Vet Med Assoc 216:1775–1779.
685 Theon, A.P., C. Rodriguez, and B.R. Madewell. 1997. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 210:778–784.
686 Thompson, J.P., N. Ackerman, J.R. Bellah, et al. 1992. 192iridium brachytherapy, using an intracavitary afterload device, for treatment of intranasal neoplasms in dogs. Am J Vet Res 53:617–622.
687 Thompson, J.P. and M.J. Fugent. 1992. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 200:531–533.
688 Thompson, J.J., D.L. Pearl, J.A. Yager, et al. 2011a. Canine subcutaneous mast cell tumor: Characterization and prognostic indices. Vet Pathol 48:156–168.
689 Thompson, J.J., J.A. Yager, S.J. Best, et al. 2011b. Canine subcutaneous mast cell tumors: Cellular proliferation and Kit expression as prognostic indices. Vet Pathol 48:169–181.
690 Thomson, M.J., S.J. Withrow, W.S. Dernell, et al. 1999. Intermuscular lipomas of the thigh region in dogs: 11 cases. J Am Anim Hosp Assoc 35:165–167.
691 Thrall, D.E. 1981. Orthovoltage radiotherapy of oral fibrosarcomas in dogs. J Am Vet Med Assoc 179:159–162.
692 Thrall, D.E., S.J. Withrow, B.E. Powers, et al. 1990. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: A dose response assay. Int J Radiat Oncol Biol Phys 18:1351–1357.
693 Tilmant, L.L., N.T. Gorman, N. Ackerman, et al. 1986. Chemotherapy of synovial cell sarcoma in a dog. J Am Vet Med Assoc 188:530–532.
694 Tobin, R.L., R.W. Nelson, M.D. Lucroy, et al. 1999. Outcome of surgical versus medical treatment of dogs with beta cell neoplasia: 39 cases (1990–1997). J Am Vet Med Assoc 215:226–230.
695 Tomamassini, M., N. Ehrhart, A. Ferretti, et al. 2000. Bone transport osteogenesis for limb salvage following resection of primary bone tumors: Experience with 6 cases (1991–1996). Vet Comp Orthop Trauma 23:43–51.
696 Tomlin, J.L., C. Sturgeon, M.J. Pead, et al. 2000. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 147:129–132.
697 Tran, C.M., A.S. Moore, and A.E. Frimberger. 2016. Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Vet Comp Oncol 14(3):252–262.
698 Trepanier, L.A. 2007. Pharmacologic management of feline hyperthyroidism. Vet Clin North Am Small Anim Pract 37:775–788, vii.
699 Trepanier, L.A., S.B. Hoffman, M. Kroll, et al. 2003. Efficacy and safety of once versus twice daily administration of methimazole in cats with hyperthyroidism. J Am Vet Med Assoc 222:954–958.
700 Tripp, C.D., J. Fidel, C.L. Anderson, et al. 2011. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 25:278–284.
701 Trout, N.J., M.M. Pavletic, and K.H. Kraus. 1995. Partial scapulectomy for management of sarcomas in three dogs and two cats. J Am Vet Med Assoc 207:585–587.
702 Tuohy, J.L., L.E. Selmic, D.R. Worley, et al. 2014. Outcome following curative‐intent surgery for oral melanoma in dogs: 70 cases (1998–2011). J Am Vet Med Assoc 245:1266–1273.
703 Tuohy, J.L., D.R. Worley, and S.J. Withrow. 2012. Outcome following simultaneous bilateral thyroid lobectomy for treatment of thyroid gland carcinoma in dogs: 15 cases (1994–2010). J Am Vet Med Assoc 241:95–103.
704 Turek, M.M., L.J. Forrest, W.M. Adams, et al. 2003. Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991–2001). Vet Comp Oncol 1:94–104.
705 Turrel, J.M. 1987a. Intraoperative radiotherapy of carcinoma of the prostate gland in ten dogs. J Am Vet Med Assoc 190:48–52.
706 Turrel, J.M. 1987b. Principles of radiation therapy. In Veterinary Cancer Medicine. G.H. Thielen and B.R. Madewell, editors. Philadelphia: Lea and Febiger.
707 Turrel, J.M., B.E. Kitchell, L.M. Miller, et al. 1988. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 193:936–940.
708 Turrel, J.M., M.C. McEntee, B.P. Burke, et al. 2006. Sodium iodide I 131 treatment of dogs with nonresectable thyroid tumors: 39 cases (1990–2003). J Am Vet Med Assoc 229:542–548.
709 Upton, M.L., C.H. Tangner, and M.E. Payton. 2006. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. J Am Vet Med Assoc 228:549–552.
710 U'ren, L.W., B.J. Biller, R.E. Elmslie, et al. 2007. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 21:113–120.
711 Vail, D.M. 2007. Plasma cell tumors. In Withrow & MacEwen’s Small Animal Clinical Oncology, 4th edition. S.J. Withrow and D.M. Vail, editors. St. Louis: Saunders.
712 Vail, D.M., A.E. Hershey, and A.S. Moore. 2000. Efficacy of adjuvant inhalational chemotherapy following surgical cytoreduction in dogs with spontaneously arising node positive primary lung cancer. In Proceedings Annual Meeting of American Association for Cancer Research, San Francisco, (abstract 1272). Philadephia: American Association for Cancer Research.
713 Vail, D.M., E.G. MacEwen, I.D. Kurzman, et al. 1995. Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: A randomized multi‐institutional clinical trial. Clin Cancer Res 1:1165–1170.
714 Vail, D.M., B.E. Powers, D.M. Getzy, et al. 1994. Evaluation of prognostic factors for dogs with synovial sarcoma: 36 cases (1986–1991). J Am Vet Med Assoc 205:1300–1307.
715 Vail, D.M., H. Von Euler, A.W. Rusk, et al. 2012. A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. J Vet Intern Med 26:598–607.
716 Vail, D.M. and K.M. Young. 2007. Canine lymphoma and lymphoid leukaemia. In Withrow & MacEwen’s Small Animal Clinical Oncology, 4th edition. S.J. Withrow and D.M. Vail, editors. St. Louis: Saunders.
717 Valerius, K.D., G.K. Ogilvie, C.H. Mallinckrodt, et al. 1997a. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987–1995). J Am Vet Med Assoc 210:512–516.
718 Valerius, K.D., B.E. Powers, M.A. Mcpherron, et al. 1997b. Adenomatous polyps and carcinoma in situ of the canine colon and rectum: 34 cases (1982–1994). J Am Anim Hosp Assoc 33:156–160.
719 Van
